Hologic, Inc. $HOLX Shares Purchased by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP grew its position in Hologic, Inc. (NASDAQ:HOLX) by 163.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,737 shares of the medical equipment provider’s stock after buying an additional 29,009 shares during the quarter. Brevan Howard Capital Management LP’s holdings in Hologic were worth $3,154,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Cinctive Capital Management LP boosted its holdings in Hologic by 53.4% during the 3rd quarter. Cinctive Capital Management LP now owns 66,404 shares of the medical equipment provider’s stock valued at $4,482,000 after acquiring an additional 23,119 shares during the period. Bank of Nova Scotia increased its stake in Hologic by 355.5% during the third quarter. Bank of Nova Scotia now owns 116,456 shares of the medical equipment provider’s stock worth $7,860,000 after purchasing an additional 90,888 shares during the period. Boothbay Fund Management LLC acquired a new stake in shares of Hologic during the third quarter worth about $433,000. Aquatic Capital Management LLC purchased a new position in shares of Hologic in the third quarter valued at approximately $1,730,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Hologic during the 3rd quarter worth approximately $1,089,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HOLX shares. BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective for the company. in a research note on Friday, November 21st. Evercore downgraded Hologic from an “outperform” rating to an “in-line” rating and decreased their price target for the stock from $79.00 to $78.00 in a report on Monday, January 5th. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Two research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat, Hologic has an average rating of “Hold” and a consensus target price of $78.42.

Hologic Stock Performance

Hologic stock opened at $75.15 on Tuesday. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $75.75. The company has a market capitalization of $16.78 billion, a price-to-earnings ratio of 31.31, a PEG ratio of 2.24 and a beta of 0.73. The stock has a fifty day moving average of $75.14 and a two-hundred day moving average of $72.78. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. Hologic’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter last year, the company posted $0.87 earnings per share. On average, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.